From HandWiki
Short description: Chemical compound
Clinical data
Other namesFananserin
ATC code
  • none
CAS Number
PubChem CID
Chemical and physical data
Molar mass425.52 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the 5HT2A receptor,[1] and the Dopamine D4 receptor,[2] but without blocking other dopamine receptors such as D2.[3] It has sedative[4] and antipsychotic effects, and has been researched for the treatment of schizophrenia,[5] although efficacy was less than expected and results were disappointing.[6]


  1. "Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists". Journal of Medicinal Chemistry 34 (8): 2477–83. August 1991. doi:10.1021/jm00112a025. PMID 1908521. 
  2. "The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor". European Journal of Pharmacology 314 (1–2): 229–33. October 1996. doi:10.1016/s0014-2999(96)00554-7. PMID 8957240. 
  3. "Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist". British Journal of Pharmacology 105 (1): 27–36. January 1992. doi:10.1111/j.1476-5381.1992.tb14206.x. PMID 1596688. 
  4. "RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats". Sleep 15 (2): 119–24. April 1992. doi:10.1093/sleep/15.2.119. PMID 1579785. 
  5. "A bridging study of fananserin in schizophrenic patients". Psychopharmacology Bulletin 34 (4): 811–8. 1998. PMID 10513457. 
  6. "Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia". The American Journal of Psychiatry 156 (3): 419–25. March 1999. doi:10.1176/ajp.156.3.419. PMID 10080558.